Skip to content
Search

Latest Stories

Committee removes pharmacist from GPhC Register to maintain public confidence in profession

The General Pharmaceutical Council (GPhC) Fitness to Practise Committee decided to remove a pharmacist from the GPhC Register at a ‘remote videolink’ hearing held on 13 – 14 April.

“The decision will not take effect until 12 May 2023 or, if an appeal is lodged, once that appeal has been concluded,” the committee said.


Kapil Ramesh Rabadia, a pharmacist first registered on 25 July 2011 with GPhC under registration number 2075823 was convicted of ‘fraud by abuse of position’ and ‘being concerned in supplying controlled drugs’ following a guilty plea on 13 September 2021.

He was sentenced to 12 months imprisonment for the fraud by abuse of position and six months in respect of supplying a 3 Class B drug. However, the interim suspension set out in the decision takes effect immediately and will lapse when the removal decision takes effect or once any appeal is concluded.

Between May 2018 and June 2019, Kapil ordered codeine linctus and Phenergan in excess of 100 bottles of each for four men who threatened him with knives and guns. The men told the pharmacist that he needed to continue to make the supplies or “there would be consequences” for him and his family.

Committee’s View

The Committee considered that the Pharmacist’s conduct and the convictions are very serious. It said, Kapil ‘facilitated the 11 removal of over 2000 bottles of codeine linctus along with Phenergan from the pharmacy premises, knowing they were to be diverted to be used recreationally, with the potential risk of harm to users which that would entail.

It is of the view that the Pharmacist’s conviction for fraud by abuse of position and supplying a controlled drug (Class B), is one that goes directly to the heart of his role as a trusted member of the pharmacy profession.

“He breached that trust repeatedly over a sustained period. Despite the coercion he faced, he made no attempt to seek help or report what was going on until he was forced to by his employer’s findings,” said the committee.

The committee considers the removal from the Register is the only sanction which will adequately protect the public, and mark the gravity of the Kapil’s conviction, by maintaining public confidence in the profession, and in the regulator, and upholding proper standards of behavior.

It has found that the Kapil’s convictions and sentence are fundamentally incompatible with remaining on the Register, not only because there remains a risk that the Registrant might repeat his conduct, and this could pose a risk of harm to the public, but also given the public interest issues which the Committee has found to be engaged by the facts of this case.

The Committee considered that, in failing to report the coercion either to his employer or to the police, the Registrant breached Standards 2 and 8 of the GPhC Standard.

It added: “He had a professional duty to promptly report the concerns he had about what was happening and instead he continued to supply dangerous medication, knowing full well where that medication would end up. Kapil only admitted what he was doing after he was confronted by his employer. As a result of his failure to speak 12 up, over 2000 bottles of codeine linctus made their way out of the legitimate supply chain and very likely ended up being misused by vulnerable individuals.”

Kapil’s Submission

In his submission to the Committee, Kapil unequivocally accepted that his fitness to practise was impaired at the time of his convictions and of the conduct on which they were based. He also accepted that he ought not to be allowed to return to practice until his suspended sentence has elapsed, in November 2023. However, he had already been suspended from practice for four years and so he hoped that after the end of his suspended sentence, following a review, he would be allowed to return to the register.

He understood and said: “I do believe that my actions had an impact on public safety”. He said that he should have been struck off the register three or four years ago closer to the time the events came to light. However, he asked the Committee to take into account that he has now been suspended for four years and if he were to be removed today then he would not be able to apply for restoration for another five years. This would mean, in effect, a sanction of nine years or more, and the delays since the events were through no fault of his. If suspended today, however, he would have the opportunity to return in about a year and prove further how he has changed at a review hearing.

The Committee was mindful that the purpose of sanction in regulatory proceedings is not to punish the pharmacist, but to protect patients and the wider public interest. However, the effect of some sanctions may be punitive. It added: “The Committee should balance the public interest against the Kapil’s own interests and should apply the principle of proportionality.”

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less